[1] McCutchan FE. Understanding the genetic diversity of HIV-1. AIDS, 2000; 14, S31-S44. doi:  10.1097/00002030-200001070-00004
[2] Taylor BS, Sobieszczyk ME, McCutchan FE, et al. The challenge of HIV-1 subtype diversity. N Engl J Med, 2008; 358, 1590-602. doi:  10.1056/NEJMra0706737
[3] He X, Xing H, Ruan Y, et al. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. Plos One, 2012; 7, e47289. doi:  10.1371/journal.pone.0047289
[4] Lu L, Jia M, Ma Y, et al. The changing face of HIV in China. NATURE, 2008; 455, 609-11. http://www.chemeurope.com/en/publications/496640/the-changing-face-of-hiv-in-china.html
[5] Moutouh L, Corbeil J, Richman DD. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci, 1996; 93, 6106-11. doi:  10.1073/pnas.93.12.6106
[6] Piyasirisilp S, McCutchan FE, Carr JK, et al. A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol, 2000; 74, 11286-95. doi:  10.1128/JVI.74.23.11286-11295.2000
[7] Sticht J, Humbert M, Findlow S, et al. A peptide inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol, 2005; 12, 671-7. doi:  10.1038/nsmb964
[8] Cromm PM, Spiegel J, Grossmann TN. Hydrocarbon stapled peptides as modulators of biological function. Acs Chem Biol, 2015; 10, 1362-75. doi:  10.1021/cb501020r
[9] Kritzer JA. Stapled peptides: Magic bullets in nature's arsenal. Nat Chem Biol, 2010; 6, 566-7. doi:  10.1038/nchembio.407
[10] Schafmeister CE, Po J, Verdine GL. An All-Hydrocarbon Cross-Linking System for Enhancing the Helicity and Metabolic Stability of Peptides. J Am Chem Soc, 2000; 122, 5891-2. doi:  10.1021/ja000563a
[11] Zhang H, Zhao Q, Bhattacharya S, et al. A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol, 2008; 378, 565-80. doi:  10.1016/j.jmb.2008.02.066
[12] Zhang H, Curreli F, Waheed AA, et al. Dual-acting stapled peptides target both HIV-1 entry and assembly. Retrovirology, 2013; 10, 136. doi:  10.1186/1742-4690-10-136
[13] Yu X, Yuan L, Huang Y, et al. Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors. Plos One, 2011; 6, e17605. doi:  10.1371/journal.pone.0017605
[14] Huang Y, Wang X, Yu X, et al. Inhibitory activity of 9-phenylcyclohepta[d]pyrimidinedione derivatives against different strains of HIV-1 as non-nucleoside reverse transcriptase inhibitors. Virol J, 2011; 8, 230. doi:  10.1186/1743-422X-8-230
[15] Liao L, Xing H, Li X, et al. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 isolates from recently infected injecting drug users in western China. AIDS Res Hum Retroviruses, 2007; 23, 1062-5. doi:  10.1089/aid.2007.23.issue-8
[16] Chong H, Hong K, Zhang C, et al. Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China. J Acquir Immune Defic Syndr, 2008; 47, 535-43. doi:  10.1097/QAI.0b013e3181663967
[17] Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol, 2005; 79, 10108-25. doi:  10.1128/JVI.79.16.10108-10125.2005
[18] Shao Y. AIDS epidemic at age 25 and control efforts in China. Retrovirology, 2006; 3, 87. doi:  10.1186/1742-4690-3-87
[19] Wu Z, Sullivan SG, Wang Y, et al. Evolution of China's response to HIV/AIDS. Lancet, 2007; 369, 679-90. doi:  10.1016/S0140-6736(07)60315-8
[20] Li T, Dai Y, Kuang J, et al. Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. Plos One, 2008; 3, e3918. doi:  10.1371/journal.pone.0003918
[21] Zhang F, Dou Z, Yu L, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis, 2008; 47, 825-33. doi:  10.1086/592260
[22] Ma L, Huang J, Xing H, et al. Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype B' strains from former blood donors in central Chinese provinces. AIDS Res Hum Retroviruses, 2010; 26, 1007-13. doi:  10.1089/aid.2009.0252
[23] Zuo Z, Liang S, Sun X, et al. Drug Resistance and Virological Failure among HIV-Infected Patients after a Decade of Antiretroviral Treatment Expansion in Eight Provinces of China. Plos One, 2016; 11, e0166661. doi:  10.1371/journal.pone.0166661
[24] Huang Y, Li Z, Xing H, et al. Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strains. Plos One, 2014; 9, e93804. doi:  10.1371/journal.pone.0093804
[25] Zhang L, Ma L, Wang Z, et al. Alterations in HIV-1 gp120 V3 region are necessary but not sufficient for coreceptor switching in CRF07_BC in China. Plos One, 2014; 9, e93426. doi:  10.1371/journal.pone.0093426
[26] Holguín A, Faudon JL, Labernardière JL, et al. Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide. J Clin Virol, 2007; 38, 176-80. doi:  10.1016/j.jcv.2006.09.002
[27] Holguín A, Ramírez de Arellano E, Rivas P, et al. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev, 2006; 8, 98-107. https://www.researchgate.net/publication/6938102_Efficacy_of_antiretroviral_therapy_in_individuals_infected_with_HIV-1_non-B_subtypes
[28] Frater J. The impact of HIV-1 subtype on the clinical response on HAART. J HIV Ther, 2002; 7, 92-6. http://europepmc.org/abstract/MED/12733607